Synonym
                                        Setileuton tosylate; Setileuton; MK-0633 Tosylate; MK0633 Tosylate; MK 0633 Tosylate
                                     
                                    
                                        IUPAC/Chemical Name
                                        4-(4-Fluorophenyl)-7-[[[5-[(1S)-1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-oxadiazol-2-yl]amino]methyl]-2H-1-benzopyran-2-one Tosylate
                                     
                                    
                                        InChi Key
                                        NDAZWYKPMVDGGE-BOXHHOBZSA-N
                                     
                                    
                                        InChi Code
                                        InChI=1S/C22H17F4N3O4.C7H8O3S/c1-2-21(31,22(24,25)26)19-28-29-20(33-19)27-11-12-3-8-15-16(10-18(30)32-17(15)9-12)13-4-6-14(23)7-5-13;1-6-2-4-7(5-3-6)11(8,9)10/h3-10,31H,2,11H2,1H3,(H,27,29);2-5H,1H3,(H,8,9,10)/t21-;/m0./s1
                                     
                                    
                                        SMILES Code
                                        O=C1C=C(C2=CC=C(F)C=C2)C3=CC=C(CNC4=NN=C([C@@](C(F)(F)F)(O)CC)O4)C=C3O1.OS(=O)(C5=CC=C(C)C=C5)=O
                                     
                                    
                                    
                                        Purity
                                        >98% (or refer to the Certificate of Analysis)
                                     
                                    
                                        Shipping Condition
                                        Shipped under ambient temperature as non-hazardous chemical.  This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
                                     
                                    
                                        Storage Condition
                                        Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
                                     
                                    
                                        Solubility
                                        Soluble in DMSO
                                     
                                    
                                        Shelf Life
                                        >3 years if stored properly
                                     
                                    
                                        Drug Formulation
                                        This drug may be formulated in DMSO
                                     
                                    
                                        Stock Solution Storage
                                        0 - 4 C for short term (days to weeks), or -20 C for long term (months).
                                     
                                    
                                        HS Tariff Code
                                        2934.99.9001
                                     
                                    
                                        More Info
                                        
                                            
                                                The most common inflammatory disease of the airways is asthma among children affecting around 235 million people worldwide. 5-Lipoxygenase (5-LOX) is a crucial enzyme which helps in the conversion of arachidonic acid (AA) to leukotrienes (LTs), the lipid mediators. It is associated with several inflammation related disorders such as asthma, allergy, and atherosclerosis. Therefore, it is considered as a promising target against inflammation and asthma
5-LO inhibitors have potential therapeutic utility for the treatment of inflammatory disorders. Asthma, an inflammatory disorder of the lower airway, is characterized by variable and reversible bronchoconstriction, airway edema, mucus secretion, and airway remodeling, which leads to recurrent episodes of wheezing, breathlessness, chest tightness, and coughing
                                            
                                         
                                     
                                 
                             
                            
                                                        
                                                                
                                    Preparing Stock Solutions
                                    
                                        The following data is based on the
                                        product
                                        molecular weight
                                        635.59
                                        Batch specific molecular weights may vary
                                        from batch to batch
                                        due to the degree of hydration, which will
                                        affect the solvent
                                        volumes required to prepare stock solutions.
                                    
                                    
                                    
                                        
                                            
                                            
                                                | Concentration / Solvent Volume / Mass | 
                                                1 mg | 
                                                5 mg | 
                                                10 mg | 
                                            
                                            
                                            
                                            
                                                | 1 mM | 
                                                1.15 mL | 
                                                5.76 mL | 
                                                11.51 mL | 
                                            
                                            
                                                | 5 mM | 
                                                0.23 mL | 
                                                1.15 mL | 
                                                2.3 mL | 
                                            
                                            
                                                | 10 mM | 
                                                0.12 mL | 
                                                0.58 mL | 
                                                1.15 mL | 
                                            
                                            
                                                | 50 mM | 
                                                0.02 mL | 
                                                0.12 mL | 
                                                0.23 mL | 
                                            
                                            
                                        
                                     
                                 
                                                             
                            
                            
                                
                                    1: Sinha S, Doble M, Manju SL. 5-Lipoxygenase as a drug target: A review on trends in inhibitors structural design, SAR and mechanism based approach. Bioorg Med Chem. 2019 Sep 1;27(17):3745-3759. doi: 10.1016/j.bmc.2019.06.040. Epub 2019 Jul 4. PMID: 31331653.
2: Maciolek CM, Ma B, Menzel K, Laliberte S, Bateman K, Krolikowski P, Gibson CR. Novel cytochrome P450-mediated ring opening of the 1,3,4-oxadiazole in setileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos. 2011 May;39(5):763-70. doi: 10.1124/dmd.110.037366. Epub 2011 Feb 16. PMID: 21325431.
3: Ducharme Y, Blouin M, Brideau C, Châteauneuf A, Gareau Y, Grimm EL, Juteau H, Laliberté S, MacKay B, Massé F, Ouellet M, Salem M, Styhler A, Friesen RW. The discovery of setileuton, a potent and selective 5-lipoxygenase inhibitor. ACS Med Chem Lett. 2010 Apr 13;1(4):170-4. doi: 10.1021/ml100029k. PMID: 24900191; PMCID: PMC4007958.